Thursday, 22 Jun 2017

You are here

Pregnancy in Lupus

Today’s session by Fischer-Betz Rebecca from Germany was very interesting. Young patients with systemic lupus erythematosus (SLE) get diagnosed before they have completed their families. About 30 or 40 years ago, most rheumatologists were not recommending pregnancy for their lupus patients. However, in recent times, outcomes have considerably improved. We should keep in mind that SLE does increase risk of pregnancy complications for both the mother and the child as compared to healthy women. For mothers, it increases risk of SLE flares, preeclampsia and overall medical complications. For the children, the complications include late and early fetal loss, growth retardation, neonatal lupus and congenital heart blocks.

Complications during pregnancy increase with these risk factors:

  • Active disease within 6 months prior to conception

  • Active lupus nephritis

  • Preexisting renal disease, especially renal damage

  • Associated antiphopholipid antibody syndrome

  • Chronic hypertension

  • Use of glucocorticoids (> 10-20 mg /day)

  • Discontinuation of hydroxychloroquine

Often even high-risk SLE patients get pregnant due to a strong desire to conceive.  Cornerstones of care of SLE patients who get pregnant are awareness of the disease and complications both by the physicians and patients. A multidisciplinary team approach should be used and importance of needed immunosuppression must be emphasized.

 

Pre-pregnancy counselling and appropriate management during early pregnancy improves pregnancy outcomes significantly.  Individual patients should be risk stratified and informed about them. All medications must be reviewed and comorbidities must be identified and treated. EULAR guidelines published in 2016 are useful.

Add new comment

More Like This

EULAR 2017 – Day 4 Highlights

Saturday was a day of big posters and special seminars at EULAR in Madrid.  In the morning, I passed on an interesting session on nailfold capillaroscopy led by Dr. M Cutolo and went to a JIA outcomes session. I reported on this in a video from day 4 (Saturday) called “Long-Term Comorbidities in JIA” – you can find it here.

Responder Criteria for Nonpharmalogical Treatment of Fibromyalgia.

Because of the subjective nature of fibromyalgia symptoms, tools for monitoring of disease activity and/or treatment assessment tools to evaluate effectiveness of nonpharmacological modalities are difficult to develop.

Concomitant Septic Arthritis and Crystalline Arthropathy

Researchers sought to describe the characteristics of patients with concurrent septic and crystal arthritis through a retrospective analysis of patients with the concomitant diagnoses between 1985-2015 at a university hospital in Spain.

EULAR 2017 – Day 3 Highlights

Friday was a mega-day in Madrid as this day all the late-breaking abstracts were presented, in addition to the bulk of high-impact podium presentations in several areas.

Here are the major presentations from several clinical areas.

Herpes Zoster

Today during the comorbidities in RA session, Dr. Leonard Calabrese spoke about herpes zoster (HZ). Given the frequency of HZ in immunocompetent persons and the fact that patients with IMIDs carry at least twice the risk of developing HZ, it is important for rheumatologists to be informed about diagnosis, treatment and most importantly prevention of HZ.